Sign in
Taking peopleNo phase

Danish Vulva Cancer Recurrence Study

Key facts

Who runs it
University of Aarhus
Where
Denmark2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
1,295 people, planned
Started
15 Aug 2024
Expected to end
31 Dec 2030
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Measurement of circulating tumor-DNA
  • Collection of patient-reported outcomes
  • Algorithmically determined telephone interview with a nurse
Record updated
29 April 2026

Who can take part

Age
18 years and older
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Primary or recurrent biopsy-verified squamous cell carcinoma of the vulva
  • ≥ 18 years of age
  • Able to understand oral and written information in Danish

Who cannot take part

  • Active treatment for concurrent cancer and/or dissemination of concurrent cancer

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The overall aim is to investigate different aspects of recurrence detection in women with vulva cancer (VC) to identify optimal treatment- and surveillance programs.

Read full original descriptionShow less

DaVulvaRec is a Danish nationwide multicenter study with patient inclusion from Aarhus University Hospital and Rigshospitalet, Denmark. Applying a mixed method research design, the investigators will collect and analyze patient-reported outcome measures in combination with procedural data to evaluate symptomatology and map actions taken during the patient's pathway from primary disease to recurrence. Furthermore, the investigators aim to examine if circulating tumor-DNA (ctDNA) can be detected in liquid biopsies from VC patients. All patients will be followed for two years or until recurrence. Patient-reported outcome measures will be completed every four months during surveillance, and liquid biopsies will be collected prospectively for later analyses.

Total number of patients to be included is 295 according to a power calculation. All patients in the clinical study will be included in the intervention group, while data on a historical control group will be obtained from The Danish Gynecological Cancer Database. Hence, the control group will consist of 1000 VC patients diagnosed between 2011-2022.

Hypotheses:

* All patients with VC will have specific tumor markers in the primary tumor that will be detectable in liquid biopsies as ctDNA at the time of diagnosis. * Measurement of ctDNA after primary treatment and during surveillance will allow detection of residual disease, improve allocation for adjuvant treatment, and will allow early detection of recurrent VC. * Proactive use of repeated PROM assessments in combination with procedural actions during surveillance will allow early detection of recurrent VC and early identification of late effects after treatment.

The 2 groups in the trial

  • PROM assessment and ctDNA detection during surveillanceTreatment being tested

    All participants (n=295) included in the prospective clinical study

    Treatment: Measurement of circulating tumor-DNA, Collection of patient-reported outcomes, and Algorithmically determined telephone interview with a nurse

  • Standard surveillanceNo study treatment, for comparison

    Historical controls (n=1,000) who will be identified by the Danish Gynecological Cancer Database

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Value of Patient-reported Outcome Measure Assessment and Circulating Tumor-DNA to Detect Early Relapse During Surveillance in Women With Vulva Cancer
Record updated
29 April 2026